Pfizer Inc. Stock
.JPG?locale=us "montechristo681")
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.100% | -5.811% | 7.734% | -26.894% | -1.264% | -18.886% | -27.269% |
| Biogen Inc. | -2.680% | -4.589% | -1.268% | -29.140% | -15.797% | -9.544% | -0.266% |
| Elanco Animal Health Inc. | 1.290% | 4.715% | 27.422% | 107.249% | 19.260% | -45.361% | - |
| AbbVie Inc. | -0.170% | -2.820% | -4.820% | 11.477% | 2.327% | 54.400% | 105.829% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before
How Much Will Pfizer Pay Out in Dividends This Year?
A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its